Evaluating clinical outcomes of PDT

T. T. Goodell, Steven Jacques, Kenton Gregory

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Citation (Scopus)

Abstract

Efficacy studies are required for regulatory approval of new medical treatments in the United States and elsewhere. Although efficacy studies may demonstrate safety and efficacy, they are not always sufficient for characterizing the effects of a treatment in actual clinical practice. Ongoing outcomes research is necessary to identify outcomes of treatment and treatment patterns in actual clinical practice. Criteria for evaluating palliative treatments in outcomes research must reflect the treatment's capacity to relieve symptoms while entailing minimal risks and adverse effects. However, the measurement of symptom relief as a result of treatment is prone to error because symptoms are inherently subjective and may be influenced by a variety of non-treatment factors, such as individual perception, physical exertion, and concurrent symptom management strategies. PDT patients treated with Photofrin® and 630-nm light at our center have had reduced dysphagia grade and stable performance status for approximately one month after PDT (N= 7-26), but these effects did not necessarily persist at the three-month followup interval. Preliminary data on five patients collected in a pilot study of a new symptom burden measurement tool suggest that the perceived burden of photosensitivity may increase with time. Fatigue, poor appetite and decreased overall quality of life appear to be the most troubling symptoms for our late-stage esophageal cancer PDT patients. The least burdensome symptoms were anxiety, pain and depression.

Original languageEnglish (US)
Title of host publicationProceedings of SPIE - The International Society for Optical Engineering
EditorsT.J. Dougherty
Pages1-9
Number of pages9
Volume4248
DOIs
StatePublished - 2001
EventOptical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy X - San Jose, CA, United States
Duration: Jan 20 2001Jan 21 2001

Other

OtherOptical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy X
CountryUnited States
CitySan Jose, CA
Period1/20/011/21/01

Fingerprint

Photosensitivity
Fatigue of materials
physical work
anxiety
pain
photosensitivity
grade
safety
cancer
intervals

Keywords

  • Outcomes research
  • Palliative care
  • Photodynamic therapy
  • Symptom measurement

ASJC Scopus subject areas

  • Electrical and Electronic Engineering
  • Condensed Matter Physics

Cite this

Goodell, T. T., Jacques, S., & Gregory, K. (2001). Evaluating clinical outcomes of PDT. In T. J. Dougherty (Ed.), Proceedings of SPIE - The International Society for Optical Engineering (Vol. 4248, pp. 1-9) https://doi.org/10.1117/12.424432

Evaluating clinical outcomes of PDT. / Goodell, T. T.; Jacques, Steven; Gregory, Kenton.

Proceedings of SPIE - The International Society for Optical Engineering. ed. / T.J. Dougherty. Vol. 4248 2001. p. 1-9.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Goodell, TT, Jacques, S & Gregory, K 2001, Evaluating clinical outcomes of PDT. in TJ Dougherty (ed.), Proceedings of SPIE - The International Society for Optical Engineering. vol. 4248, pp. 1-9, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy X, San Jose, CA, United States, 1/20/01. https://doi.org/10.1117/12.424432
Goodell TT, Jacques S, Gregory K. Evaluating clinical outcomes of PDT. In Dougherty TJ, editor, Proceedings of SPIE - The International Society for Optical Engineering. Vol. 4248. 2001. p. 1-9 https://doi.org/10.1117/12.424432
Goodell, T. T. ; Jacques, Steven ; Gregory, Kenton. / Evaluating clinical outcomes of PDT. Proceedings of SPIE - The International Society for Optical Engineering. editor / T.J. Dougherty. Vol. 4248 2001. pp. 1-9
@inproceedings{1f5689ae1c03430eb82a7d6bdd991758,
title = "Evaluating clinical outcomes of PDT",
abstract = "Efficacy studies are required for regulatory approval of new medical treatments in the United States and elsewhere. Although efficacy studies may demonstrate safety and efficacy, they are not always sufficient for characterizing the effects of a treatment in actual clinical practice. Ongoing outcomes research is necessary to identify outcomes of treatment and treatment patterns in actual clinical practice. Criteria for evaluating palliative treatments in outcomes research must reflect the treatment's capacity to relieve symptoms while entailing minimal risks and adverse effects. However, the measurement of symptom relief as a result of treatment is prone to error because symptoms are inherently subjective and may be influenced by a variety of non-treatment factors, such as individual perception, physical exertion, and concurrent symptom management strategies. PDT patients treated with Photofrin{\circledR} and 630-nm light at our center have had reduced dysphagia grade and stable performance status for approximately one month after PDT (N= 7-26), but these effects did not necessarily persist at the three-month followup interval. Preliminary data on five patients collected in a pilot study of a new symptom burden measurement tool suggest that the perceived burden of photosensitivity may increase with time. Fatigue, poor appetite and decreased overall quality of life appear to be the most troubling symptoms for our late-stage esophageal cancer PDT patients. The least burdensome symptoms were anxiety, pain and depression.",
keywords = "Outcomes research, Palliative care, Photodynamic therapy, Symptom measurement",
author = "Goodell, {T. T.} and Steven Jacques and Kenton Gregory",
year = "2001",
doi = "10.1117/12.424432",
language = "English (US)",
volume = "4248",
pages = "1--9",
editor = "T.J. Dougherty",
booktitle = "Proceedings of SPIE - The International Society for Optical Engineering",

}

TY - GEN

T1 - Evaluating clinical outcomes of PDT

AU - Goodell, T. T.

AU - Jacques, Steven

AU - Gregory, Kenton

PY - 2001

Y1 - 2001

N2 - Efficacy studies are required for regulatory approval of new medical treatments in the United States and elsewhere. Although efficacy studies may demonstrate safety and efficacy, they are not always sufficient for characterizing the effects of a treatment in actual clinical practice. Ongoing outcomes research is necessary to identify outcomes of treatment and treatment patterns in actual clinical practice. Criteria for evaluating palliative treatments in outcomes research must reflect the treatment's capacity to relieve symptoms while entailing minimal risks and adverse effects. However, the measurement of symptom relief as a result of treatment is prone to error because symptoms are inherently subjective and may be influenced by a variety of non-treatment factors, such as individual perception, physical exertion, and concurrent symptom management strategies. PDT patients treated with Photofrin® and 630-nm light at our center have had reduced dysphagia grade and stable performance status for approximately one month after PDT (N= 7-26), but these effects did not necessarily persist at the three-month followup interval. Preliminary data on five patients collected in a pilot study of a new symptom burden measurement tool suggest that the perceived burden of photosensitivity may increase with time. Fatigue, poor appetite and decreased overall quality of life appear to be the most troubling symptoms for our late-stage esophageal cancer PDT patients. The least burdensome symptoms were anxiety, pain and depression.

AB - Efficacy studies are required for regulatory approval of new medical treatments in the United States and elsewhere. Although efficacy studies may demonstrate safety and efficacy, they are not always sufficient for characterizing the effects of a treatment in actual clinical practice. Ongoing outcomes research is necessary to identify outcomes of treatment and treatment patterns in actual clinical practice. Criteria for evaluating palliative treatments in outcomes research must reflect the treatment's capacity to relieve symptoms while entailing minimal risks and adverse effects. However, the measurement of symptom relief as a result of treatment is prone to error because symptoms are inherently subjective and may be influenced by a variety of non-treatment factors, such as individual perception, physical exertion, and concurrent symptom management strategies. PDT patients treated with Photofrin® and 630-nm light at our center have had reduced dysphagia grade and stable performance status for approximately one month after PDT (N= 7-26), but these effects did not necessarily persist at the three-month followup interval. Preliminary data on five patients collected in a pilot study of a new symptom burden measurement tool suggest that the perceived burden of photosensitivity may increase with time. Fatigue, poor appetite and decreased overall quality of life appear to be the most troubling symptoms for our late-stage esophageal cancer PDT patients. The least burdensome symptoms were anxiety, pain and depression.

KW - Outcomes research

KW - Palliative care

KW - Photodynamic therapy

KW - Symptom measurement

UR - http://www.scopus.com/inward/record.url?scp=0034930502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034930502&partnerID=8YFLogxK

U2 - 10.1117/12.424432

DO - 10.1117/12.424432

M3 - Conference contribution

AN - SCOPUS:0034930502

VL - 4248

SP - 1

EP - 9

BT - Proceedings of SPIE - The International Society for Optical Engineering

A2 - Dougherty, T.J.

ER -